These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3081727)

  • 21. An acellular vaccine from Pseudomonas aeruginosa: homologous and crossed protection between serogroups according to Habs' classification.
    Berche P; Véron M; Fermanian J; Daoulas-Lebourdelles F; Guégen A
    Ann Microbiol (Paris); 1979; 130(2):179-88. PubMed ID: 90473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pseudomonas aeruginosa infection and vaccination in the rat.
    Kostiala AA
    J Med Microbiol; 1980 May; 13(2):201-12. PubMed ID: 6770090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production and characterisation of mouse monoclonal antibodies reactive with the lipopolysaccharide core of Pseudomonas aeruginosa.
    Nelson JW; Barclay GR; Micklem LR; Poxton IR; Govan JR
    J Med Microbiol; 1992 May; 36(5):358-65. PubMed ID: 1588587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K; Wiener-Kronish JP; Sawa T
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine.
    Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH
    J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Experimental infection of immunized mice homologous and heterologous serotypes with Pseudomonas aeruginosa].
    Vidal G; Mynard MC
    Ann Inst Pasteur (Paris); 1972 Jun; 122(6):1129-35. PubMed ID: 4627762
    [No Abstract]   [Full Text] [Related]  

  • 27. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa.
    Collins MS; Ladehoff DK; Mehton NS; Noonan JS
    FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of stable cell lines producing anti-Pseudomonas aeruginosa monoclonal antibodies and their protective effects for the infection in mice.
    O'Oka H; Chonan E; Mizutani K; Fukuda T; Kuroiwa Y; Ono Y; Shigeta S
    Microbiol Immunol; 1992; 36(12):1305-16. PubMed ID: 1287405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new polyvalent Pseudomonas vaccine.
    Miler JM; Spilsbury JF; Jones RJ; Roe EA; Lowbury EJ
    J Med Microbiol; 1977 Feb; 10(1):19-27. PubMed ID: 402473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.
    Zweerink HJ; Gammon MC; Hutchison CF; Jackson JJ; Lombardo D; Miner KM; Puckett JM; Sewell TJ; Sigal NH
    Infect Immun; 1988 Aug; 56(8):1873-9. PubMed ID: 3135264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subdivision of O serotypes of Pseudomonas aeruginosa with monoclonal antibodies.
    Vale TA; Gaston MA; Pitt TL
    J Clin Microbiol; 1988 Sep; 26(9):1779-82. PubMed ID: 3141466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of protective mAbs against Pseudomonas aeruginosa outer membrane protein I by C1q binding assay.
    Eckhardt A; Heiss MM; Ehret W; Permanetter W; Duchêne M; Domdey H; von Specht BU
    Zentralbl Bakteriol; 1991 Apr; 275(1):100-11. PubMed ID: 1930557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinico-immunological trials of Pseudomonas aeruginosa vaccine.
    Stanislavsky ES; Balayan SS; Sergienko AI; Makarenko TA; Edvabnaya LS; Krohina MA; Rusanov VM
    Vaccine; 1991 Jul; 9(7):491-4. PubMed ID: 1910233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][].
    von Specht BU
    Zentralbl Chir; 1999; 124(4):298-302. PubMed ID: 10355084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme-linked immunosorbent assay (ELISA) and a passive haemagglutination test (PHT) for the detection of pseudomonas antibodies in burned patients.
    Roe EA; Jones RJ
    Burns Incl Therm Inj; 1985 Apr; 11(4):252-8. PubMed ID: 3924353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surveillance of gram-negative bacteria for Pseudomonas aeruginosa lipoprotein I using a monoclonal antibody.
    Sciortino CV
    Hybridoma; 1993 Jun; 12(3):327-32. PubMed ID: 7689535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection.
    Okada K; Kawaharajo K; Kasai T; Homma JY
    Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
    Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
    Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 40. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
    Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
    J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.